Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 14/20 | 1.00 |
| ▸ | TNKS | O95271 | 13/20 | 1.00 |
| ▸ | SULT2A1 | Q06520 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29372843 | 1.00 | TNKS2 (1.00) | TNKS2TNKSSULT2A1MAOAMAOB | |
| SCHEMBL9904844 | 1.00 | TNKS2 (1.00) | TNKS2TNKSSULT2A1MAOAMAOB | |
| SCHEMBL35212190 | 1.00 | TNKS2 (1.00) | TNKS2TNKSSULT2A1MAOAMAOB | |
| SCHEMBL23772382 | 0.93 | TNKS (0.86) | TNKS2TNKSSULT2A1HPGDSMN1; SMN2 | |
| SCHEMBL9905155 | 0.93 | TNKS (0.86) | TNKS2TNKSSULT2A1MAOAMAOB | |
| SCHEMBL9905154 | 0.93 | TNKS (0.86) | TNKS2TNKSSULT2A1MAOAMAOB | |
| SCHEMBL9926244 | 0.92 | TNKS (1.00) | TNKS2TNKSSULT2A1MAOAMAOB | |
| SCHEMBL15449894 | 0.91 | TNKS (0.84) | TNKS2TNKSSULT2A1HPGDSMN1; SMN2 | |
| SCHEMBL9926210 | 0.89 | TNKS2 (0.81) | TNKS2TNKSSULT2A1HSD11B1METAP2 | |
| SCHEMBL15449865 | 0.88 | TNKS2 (0.79) | TNKS2TNKSSULT2A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170065587-A1 | ANTIVIRAL AXIN STABLIZER | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY | 2017-03-09 | — | — | US | claimed |
| US-20210353681-A1 | USE OF TNKS INHIBITORS FOR REGENERATION OF CARTILAGE | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2021-11-18 | — | — | US | disclosed |
| US-10722484-B2 | Methods of cancer treatment | K-GEN, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190298679-A1 | METHODS OF CANCER TREATMENT | K-GEN THERAPEUTICS, INC. | 2019-10-03 | — | — | US | disclosed |
| US-10064862-B2 | Antiviral axin stabilizer | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) | 2018-09-04 | — | — | US | disclosed |
| WO-2017116064-A1 | BIOMARKER DKK FOR PREDICTING EFFICACY OF C-MET INHIBITOR | 삼성전자 주식회사 | 2017-07-06 | — | — | WO | disclosed |
| US-20170065587-A1 | ANTIVIRAL AXIN STABLIZER | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY | 2017-03-09 | — | — | US | disclosed |
| US-9403812-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2016-08-02 | — | — | US | disclosed |
| US-20150322057-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-11-12 | — | — | US | disclosed |
| US-9096587-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-08-04 | — | — | US | disclosed |
| US-20140031374-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO University Hospital, HF (NO) | 2014-01-30 | — | — | US | disclosed |
| EP-2649063-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | Oslo University Hospital HF (NO) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012076898-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190298679-A1 | METHODS OF CANCER TREATMENT | PRKCI, PRKCH, PRKCZ | TNKS2 199/4885TNKS 435/4885SULT2A1 4791/4885 |
| US-10064862-B2 | Antiviral axin stabilizer | IRF3, AXIN2, TANK | TNKS2 10/4885TNKS 4/4885SULT2A1 4293/4885 |
| US-20150322057-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | CTNNB1, WNT1, CTNNA1 | TNKS2 167/4885TNKS 118/4885SULT2A1 1173/4885 |
| US-10722484-B2 | Methods of cancer treatment | PRKCI, PRKCH, PRKCZ | TNKS2 199/4885TNKS 435/4885SULT2A1 4791/4885 |
| US-20140031374-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | CTNNB1, WNT1, CTNNA1 | TNKS2 191/4885TNKS 145/4885SULT2A1 1203/4885 |
| US-20170065587-A1 | ANTIVIRAL AXIN STABLIZER | TNKS1BP1, TNKS, TANK | TNKS2 7/4885TNKS 2/4885SULT2A1 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.